Risk-sharing in the Pharmaceutical Industry The Case of Out-licensing /
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awdur Corfforaethol: | |
| Fformat: | Electronig eLyfr |
| Iaith: | English |
| Cyhoeddwyd: |
Heidelberg :
Physica-Verlag HD : Imprint: Physica,
2006.
|
| Rhifyn: | 1st ed. 2006. |
| Cyfres: | Contributions to Management Science,
|
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1007/3-7908-1668-X |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Tabl Cynhwysion:
- Key Issues in Managing Pharmaceutical Innovation
- Risk-sharing as New Paradigm in Pharma R&D Collaborations
- Case Studies on Risk-sharing in Pharma R&D Collaborations
- Characteristics of Risk-sharing in Pharma R&D Collaborations
- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
- Conclusion.